Hormonal
For patients with type 2 diabetes and established cardiovascular disease, a combination of metformin and a glucagon-like peptide-1 (GLP-1) receptor agonist with proven cardiovascular benefits is recommended.
If you have Type 2 Diabetes and existing heart disease, your doctor should prioritize a treatment plan that includes Metformin plus a GLP-1 receptor agonist known to protect the heart. This combination is recommended over other options to reduce the risk of major cardiovascular events like heart attack or stroke.
In case of established CVD, a combination of glucagon-like peptide-1 receptor agonist with proven CV benefits is recommended along with metformin
Why this rating
Based on Cardiovascular Outcome Trials (CVOTs) and consensus grading (Grade A/B implied by strong recommendation).
Source
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases
Alaaeldin Bashier et al. · Diabetology & Metabolic Syndrome · 2019
DOI 10.1186/s13098-019-0476-0
More from this paper
- Lifestyle modifications, including Medical Nutritional Therapy (MNT), are essential for maintaining the effectiveness of pharmacological therapies in managing T2DM and CVD.Limited
- For patients with Type 2 Diabetes and chronic kidney disease (CKD) or heart failure (HF), a sodium-glucose transporter protein-2 (SGLT-2) inhibitor with proven cardiovascular benefit is advised.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →